CoChat
Sign Up
Cited by 18

Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study)

Yrondi, Antoine, Aouizerate, Bruno, El-Hage, Wissam, Moliere, Fanny, Thalamas, Claire, Delcourt, Nicolas, Sporer, Marie, Taib, Simon +27 more·2018·Frontiers in Psychiatry
DOI 10.3389/fpsyt.2018.00326PMC PMC6066663
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2018.00326

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 81

  1. [1]Sartorius N. The economic and social burden of depression. J Clin Psychiatry (2001) 62(Suppl. 15): 8– 11. 11444765
  2. [2]Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry (2001) 62(Suppl. 26): 5– 9. 11775091
  3. [3]Bonicatto SC Dew MA Zaratiegui R Lorenzo L Pecina P. Adult outpatients with depression: worse quality of life than in other chronic medical diseases in Argentina. Soc Sci Med. 1982 (2001) 52: 911– 9. 10.1016/S0277-9536(00)00192-1 11234864 · DOI
  4. [4]IsHak WW Greenberg JM Balayan K Kapitanski N Jeffrey J Fathy H. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry (2011) 19: 229– 39. 10.3109/10673229.2011.614099 21916825 · DOI · Paper page
  5. [6]Consoli SM Depression and Organic Diseases Study. [Depression and associated organic pathologies, a still under-estimated comorbidity. Results of the DIALOGUE study]. Presse Méd Paris Fr 1983 (2003) 32: 10– 21. 12610390
  6. [8]Malhi GS Parker GB Crawford J Wilhelm K Mitchell PB. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. (2005) 112: 302– 9. 10.1111/j.1600-0447.2005.00602.x 16156838 · DOI
  7. [9]McIntyre RS Filteau M-J Martin L Patry S Carvalho A Cha DS. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. (2014) 156: 1– 7. 10.1016/j.jad.2013.10.043 24314926 · DOI · Paper page
  8. [10]Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int J Psychiatry (1967) 4: 203– 17. 4863731
  9. [11]Schildkraut JJ Schanberg SM Breese GR Kopin IJ. Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry (1967) 124: 600– 8. 10.1176/ajp.124.5.600 4383104 · DOI
  10. [12]Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry (2006) 67(Suppl. 4): 22– 6. 16683859
  11. [13]Capuron L Castanon N. Role of inflammation in the development of neuropsychiatric symptom domains: evidence and mechanisms. Curr Top Behav Neurosci. (2017) 31: 31– 44. 10.1007/7854_2016_14 27221626 · DOI
  12. [14]Capuron L Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. (2011) 130: 226– 38. 10.1016/j.pharmthera.2011.01.014 21334376 PMC3072299 · DOI · Paper page
  13. [15]Andersson NW Gustafsson LN Okkels N Taha F Cole SW Munk-Jørgensen P. Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychol Med. (2015) 45: 3559– 69. 10.1017/S0033291715001488 26271451 · DOI
  14. [16]Imran MY Saira Khan EA Ahmad NM Farman Raja S Saeed MA Ijaz Haider I. Depression in Rheumatoid Arthritis and its relation to disease activity. Pak J Med Sci. (2015) 31: 393– 7. 10.12669/pjms.312.6589 26101498 PMC4476349 · DOI
  15. [17]Margaretten M Julian L Katz P Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol. (2011) 6: 617– 23. 10.2217/IJR.11.6 22211138 PMC3247620 · DOI
  16. [18]Hider SL Tanveer W Brownfield A Mattey DL Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (2009) 48: 1152– 4. 10.1093/rheumatology/kep170 19608723 · DOI
  17. [20]Wium-Andersen MK Ørsted DD Nielsen SF Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry (2013) 70: 176– 84. 10.1001/2013.jamapsychiatry.102 23266538 · DOI · Paper page
  18. [21]Zalli A Jovanova O Hoogendijk WJG Tiemeier H Carvalho LA. Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology (2016) 233: 1669– 178. 10.1007/s00213-015-3919-9 25877654 PMC4828485 · DOI
  19. [22]Vogelzangs N de Jonge P Smit JH Bahn S Penninx BW. Cytokine production capacity in depression and anxiety. Transl Psychiatry (2016) 6: e825. 10.1038/tp.2016.92 27244234 PMC5070051 · DOI
  20. [23]Miller AH Maletic V Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 65: 732– 41. 10.1016/j.biopsych.2008.11.029 19150053 PMC2680424 · DOI · Paper page
  21. [24]Miller AH. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun. (2009) 23: 149– 58. 10.1016/j.bbi.2008.08.006 18793712 PMC2745948 · DOI · Paper page
  22. [25]Graeber MB Tetzlaff W Streit WJ Kreutzberg GW Microglial cells but not astrocytes undergo mitosis following rat facial nerve axotomy. Neurosci Lett. (1988) 85: 317– 21. 3362421
  23. [26]Graeber MB Kreutzberg GW. Delayed astrocyte reaction following facial nerve axotomy. J Neurocytol. (1988) 17: 209– 20. 2849645
  24. [27]Graeber MB Streit WJ. Microglia: immune network in the CNS. Brain Pathol. (1990) 1: 2– 5. 1669689
  25. [28]van Rossum D Hanisch U-K. Microglia. Metab Brain Dis. (2004) 19: 393– 411. 15554430
  26. [30]Takahashi A Flanigan ME McEwen BS Russo SJ. Aggression, Social Stress, and the Immune System in Humans and Animal Models. Front Behav Neurosci. (2018) 12: 56. 10.3389/fnbeh.2018.00056 29623033 PMC5874490 · DOI
  27. [31]Turecki G Meaney MJ. Effects of the social environment and stress on glucocorticoid receptor gene methylation: a systematic review. Biol Psychiatry (2016) 79: 87– 96. 10.1016/j.biopsych.2014.11.022 25687413 PMC4466091 · DOI · Paper page
  28. [32]Labonté B Suderman M Maussion G Navaro L Yerko V Mahar I. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry (2012) 69: 722– 31. 10.1001/archgenpsychiatry.2011.2287 22752237 PMC4991944 · DOI · Paper page
  29. [33]Zhang TY Labonté B Wen XL Turecki G Meaney MJ. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology (2013) 38: 111– 23. 10.1038/npp.2012.149 22968814 PMC3521971 · DOI · Paper page
  30. [34]Gong Q He Y. Depression, neuroimaging and connectomics: a selective overview. Biol Psychiatry (2015) 77: 223– 35. 10.1016/j.biopsych.2014.08.009 25444171 · DOI
  31. [35]Meier TB Drevets WC Wurfel BE Ford BN Morris HM Victor TA. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav Immun. (2016) 53: 39– 48. 10.1016/j.bbi.2015.11.003 26546831 PMC4783304 · DOI · Paper page
  32. [36]Savitz J Dantzer R Meier TB Wurfel BE Victor TA McIntosh SAF. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology (2015) 62: 54– 8. 10.1016/j.psyneuen.2015.07.609 26232650 PMC4637239 · DOI
  33. [37]Dannlowski U Ohrmann P Bauer J Kugel H Arolt V Heindel W. Amygdala reactivity to masked negative faces is associated with automatic judgmental bias in major depression: a 3 T fMRI study. J Psychiatry Neurosci. (2007) 32: 423– 9. 18043766 PMC2077348
  34. [39]Fu CHY Mourao-Miranda J Costafreda SG Khanna A Marquand AF Williams SCR. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol Psychiatry (2008) 63: 656– 62. 10.1016/j.biopsych.2007.08.020 17949689 · DOI
  35. [40]Keedwell PA Andrew C Williams SCR Brammer MJ Phillips ML. A double dissociation of ventromedial prefrontal cortical responses to sad and happy stimuli in depressed and healthy individuals. Biol Psychiatry (2005) 58: 495– 503. 10.1016/j.biopsych.2005.04.035 15993859 · DOI · Paper page
  36. [41]Surguladze S Brammer MJ Keedwell P Giampietro V Young AW Travis MJ. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry (2005) 57: 201– 9. 10.1016/j.biopsych.2004.10.028 15691520 · DOI · Paper page
  37. [42]Felger JC Li Z Haroon E Woolwine BJ Jung MY Hu X. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry (2015) 21: 1358– 65. 10.1038/mp.2015.168 26552591 PMC4862934 · DOI · Paper page
  38. [43]Rupprecht R Papadopoulos V Rammes G Baghai TC Fan J Akula N. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. (2010) 9: 971– 88. 10.1038/nrd3295 21119734 · DOI · Paper page
  39. [44]Hannestad J DellaGioia N Gallezot J-D Lim K Nabulsi N Esterlis I. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav Immun. (2013) 33: 131– 8. 10.1016/j.bbi.2013.06.010 23850810 PMC3899398 · DOI · Paper page
  40. [45]Setiawan E Wilson AA Mizrahi R Rusjan PM Miler L Rajkowska G. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry (2015) 72: 268– 75. 10.1001/jamapsychiatry.2014.2427 25629589 PMC4836849 · DOI · Paper page
  41. [46]Arlicot N Vercouillie J Ribeiro M-J Tauber C Venel Y Baulieu J-L Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol. (2012) 39: 570– 8. 10.1016/j.nucmedbio.2011.10.012 22172392 · DOI
  42. [48]Lavisse S García-Lorenzo D Peyronneau M-A Bodini B Thiriez C Kuhnast B Optimized quantification of translocator protein radioligand 18F-DPA-714 uptake in the brain of genotyped healthy volunteers. J Nucl Med. (2015) 56: 1048– 54. 10.2967/jnumed.115.156083 26025960 · DOI
  43. [49]Lyoo CH Ikawa M Liow J-S Zoghbi SS Morse CL Pike VW. Cerebellum can serve as a pseudo-reference region in alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. (2015) 56: 701– 6. 10.2967/jnumed.114.146027 25766898 PMC4839390 · DOI
  44. [50]Yrondi A Bennabi D Haffen E Garnier M Bellivier F Bourgerol T. Significant need for a french network of expert centers enabling a better characterization and management of treatment-resistant depression (fondation fondamental). Front Psychiatry (2017) 8: 244. 10.3389/fpsyt.2017.00244 29225582 PMC5706526 · DOI
  45. [52]Lesur A Bonnet D Vicaut E Lempérière T. [Tyrer′s Brief Scale for Anxiety used with outpatients. First validation in the French language]. L′ Encéphale (1989) 15: 535– 42. 2612426
  46. [53]Tyrer P Owen RT Cicchetti DV. The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry (1984) 47: 970– 5. 6481391 PMC1028000
  47. [55]Mabrouk R Strafella AP Knezevic D Ghadery C Mizrahi R Gharehgazlou A Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. PLoS ONE (2017) 12: e0177785 10.1371/journal.pone.0177785 28545084 PMC5435246 · DOI
  48. [56]Kuhnast B Damont A Hinnen F Catarina T Demphel S Le Helleix S [18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. (2012) 70: 489– 97. 10.1016/j.apradiso.2011.10.015 22104496 · DOI
  49. [57]Wilson AA Garcia A Parkes J McCormick P Stephenson KA Houle S. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. (2008) 35: 305– 14. 10.1016/j.nucmedbio.2007.12.009 18355686 · DOI
  50. [58]James ML Fulton RR Vercoullie J Henderson DJ Garreau L Chalon S. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. (2008) 49: 814– 22. 10.2967/jnumed.107.046151 18413395 · DOI
  51. [59]Peyronneau M-A Saba W Goutal S Damont A Dolle F Kassiou M Metabolism and Quantification of [18F]DPA-714, a New TSPO Positron Emission Tomography Radioligand. Drug Metab Dispos. (2012) 41: 122– 31. 10.1124/dmd.112.046342 23065531 · DOI
  52. [60]Kenk M Selvanathan T Rao N Suridjan I Rusjan P Remington G Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull. (2015) 41: 85– 93. 10.1093/schbul/sbu157 25385788 PMC4266311 · DOI
  53. [61]Koshimori Y Ko J-H Mizrahi R Rusjan P Mabrouk R Jacobs MF. Imaging striatal microglial activation in patients with parkinson′s disease. PLoS ONE (2015) 10: e0138721. 10.1371/journal.pone.0138721 26381267 PMC4575151 · DOI · Paper page
  54. [63]Fan Z Harold D Pasqualetti G Williams J Brooks DJ Edison P. Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort? J Nucl Med. (2015) 56: 707– 13. 10.2967/jnumed.114.149443 25840980 · DOI
  55. [64]Dowlati Y Herrmann N Swardfager W Liu H Sham L Reim EK. A meta-analysis of cytokines in major depression. Biol Psychiatry (2010) 67: 446– 57. 10.1016/j.biopsych.2009.09.033 20015486 · DOI · Paper page
  56. [65]Lecrubier Y Sheehan D Weiller E Amorim P Bonora I Harnett Sheehan K A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry (1997) 12: 224– 31. 10.1016/S0924-9338(97)83296-8 · DOI · Paper page
  57. [66]Logan J Fowler JS Volkow ND Wolf AP Dewey SL Schlyer DJ Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. (1990) 10: 740– 47. 10.1038/jcbfm.1990.127 2384545 · DOI
  58. [67]Eustache P Nemmi F Saint-Aubert L Pariente J Péran P. Multimodal magnetic resonance imaging in alzheimer′s disease patients at prodromal stage. J Alzheimers Dis. (2016) 50: 1035– 50. 10.3233/JAD-150353 26836151 PMC4927932 · DOI · Paper page
  59. [68]Péran P Cherubini A Luccichenti G Hagberg G Démonet J-F Rascol O. Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp. (2009) 30: 2667– 75. 10.1002/hbm.20698 19172651 PMC6871035 · DOI
  60. [69]Cherubini A Péran P Caltagirone C Sabatini U Spalletta G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage (2009) 48: 29– 36. 10.1016/j.neuroimage.2009.06.035 19540925 · DOI
  61. [70]Barbagallo G Sierra-Peña M Nemmi F Traon AP-L Meissner WG Rascol O. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord. (2016) 31: 325– 34. 10.1002/mds.26471 26676922 · DOI
  62. [71]Nemmi F Saint-Aubert L Adel D Salabert A-S Pariente J Barbeau EJ. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer′s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging (2014) 41: 1408– 18. 10.1007/s00259-014-2728-4 24573658 PMC5101350 · DOI
  63. [72]Lépine J-P Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. (2011) 7: 3– 7. 10.2147/NDT.S19617 21750622 PMC3131101 · DOI
  64. [73]Fava M Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. (1996) 19: 179– 200. 8827185
  65. [74]Hamon M Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry (2013) 45: 54– 63. 10.1016/j.pnpbp.2013.04.009 23602950 · DOI
  66. [76]Kim Y-K Na K-S Myint A-M Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2016) 64: 277– 84. 10.1016/j.pnpbp.2015.06.008 26111720 · DOI · Paper page
  67. [77]Rosenblat JD Cha DS Mansur RB McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry (2014) 53: 23– 34. 10.1016/j.pnpbp.2014.01.013 24468642 · DOI · Paper page
  68. [78]Wohleb ES Franklin T Iwata M Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. (2016) 17: 497– 511. 10.1038/nrn.2016.69 27277867 · DOI · Paper page
  69. [79]Osimo EF Cardinal RN Jones PB Khandaker GM. Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: an electronic health record-based study. Psychoneuroendocrinology (2018) 91: 226– 34. 10.1016/j.psyneuen.2018.02.031 29544672 PMC5910056 · DOI · Paper page
  70. [80]Fond G Hamdani N Kapczinski F Boukouaci W Drancourt N Dargel A. Effectiveness and tolerance of anti-inflammatory drugs′ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. (2014) 129: 163– 79. 10.1111/acps.12211 24215721 · DOI
  71. [81]Hannestad J DellaGioia N Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 36: 2452– 9. 10.1038/npp.2011.132 21796103 PMC3194072 · DOI · Paper page
  72. [82]O′Brien SM Scully P Fitzgerald P Scott LV Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. (2007) 41: 326– 31. 10.1016/j.jpsychires.2006.05.013 16870211 · DOI · Paper page
  73. [83]Eller T Vasar V Shlik J Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32: 445– 50. 10.1016/j.pnpbp.2007.09.015 17976882 · DOI · Paper page
  74. [84]Cattaneo A Gennarelli M Uher R Breen G Farmer A Aitchison KJ. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline “predictors” and longitudinal “targets.” Neuropsychopharmacology (2013) 38: 377– 85. 10.1038/npp.2012.191 22990943 PMC3547188 · DOI · Paper page
  75. [85]Raison CL Rutherford RE Woolwine BJ Shuo C Schettler P Drake DF. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 70: 31– 41. 10.1001/2013.jamapsychiatry.4 22945416 PMC4015348 · DOI · Paper page
  76. [86]Abbasi S-H Hosseini F Modabbernia A Ashrafi M Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. (2012) 141: 308– 14. 10.1016/j.jad.2012.03.033 22516310 · DOI
  77. [87]Yrondi A Sporer M Péran P Schmitt L Arbus C Sauvaget A. Electroconvulsive therapy, depression, the immune system and inflammation: a systematic review. Brain Stimul Basic Transl Clin Res Neuromodulation (2017) 11: 29– 51. 10.1016/j.brs.2017.10.013 29111078 · DOI
  78. [88]Jokela M Virtanen M Batty GD Kivimäki M. Inflammation and specific symptoms of depression. JAMA Psychiatry (2016) 73: 87– 8. 10.1001/jamapsychiatry.2015.1977 26579988 · DOI
  79. [89]Goldsmith DR Haroon E Woolwine BJ Jung MY Wommack EC Harvey PD. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behav Immun. (2016) 56: 281– 8. 10.1016/j.bbi.2016.03.025 27040122 PMC4939278 · DOI
  80. [90]Köhler-Forsberg O Buttenschøn HN Tansey KE Maier W Hauser J Dernovsek MZ. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain Behav Immun. (2017) 62: 344– 50. 10.1016/j.bbi.2017.02.020 28257825 · DOI · Paper page
  81. [91]Holmes SE Hinz R Conen S Gregory CJ Matthews JC Anton-Rodriguez JM. Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol Psychiatry (2018) 83: 61– 9. 10.1016/j.biopsych.2017.08.005 28939116 · DOI · Paper page

Cited by

Sorted by citations

Authors
Yrondi, A., Aouizerate, B., El-Hage, W., Moliere, F., Thalamas, C., Delcourt, N., Sporer, M., Taib, S., Schmitt, L., Arlicot, N., Meligne, D., Sommet, A., Salabert, A. S., Guillaume, S., Courtet, P., Galtier, F., Mariano-Goulart, D., Champfleur, N. M. D., Bars, E. L., Desmidt, T., Lemaire, M., Camus, V., Santiago-Ribeiro, M. J., Cottier, J. P., Fernandez, P., Meyer, M., Dousset, V., Doumy, O., Delhaye, D., Capuron, L., Leboyer, M., Haffen, E., Péran, P., Payoux, P., & Arbus, C.
Venue
Frontiers in Psychiatry
Publisher
Frontiers Media SA
Published
2018-07-24
Volume
9
ISSN
1664-0640
DOI
10.3389/fpsyt.2018.00326
PMC
PMC6066663
Cited by
18
References
10
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review